ORMP · Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals has completed a significant strategic transaction involving both the divestiture of its subsidiary and a concurrent investment in the acquiring company. The company sold its wholly-owned subsidiary Oratech Pharma to Lifeward Ltd., receiving a combination of equity, warrants, and future revenue-sharing payments as consideration. This transaction effectively monetizes Oramed's interest in Oratech while maintaining ongoing financial participation through the revenue-sharing arrangement tied to Lifeward's ReWalk Personal Exoskeleton products. Simultaneously, Oramed demonstrated confidence in Lifeward's prospects by investing $9 million through convertible notes, which provides additional equity exposure through conversion rights and accompanying warrants. The dual nature of these transactions—both closing on March 25, 2026—suggests a coordinated strategic relationship between Oramed and Lifeward, transforming Oramed from a parent company to a significant shareholder and creditor of Lifeward with multiple avenues for future value realization through equity appreciation, warrant exercises, and revenue participation.